

YCC West Midlands

**ANNUAL REPORT
2013/14**

ANNUAL REPORT OF YELLOW CARD CENTRE WEST MIDLANDS TO THE MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY

2013/14

1. STAFF

Professor R E Ferner – Director
Dr J J Coleman – Honorary Consultant Physician
Mr C Anton – Administrative Co-ordinator
Dr A R Cox – Honorary Pharmacovigilance Pharmacist
Ms M Robinson – Clerical Officer

2. SUMMARY

Our priorities for the year remain focused on teaching and providing information and we have continued our programmes for all grades of staff from nurses to consultants. We have reminded GPs of the existence of the Yellow Card scheme and distributed patient Yellow Cards about the region. We have engaged with a number of champions – nurse, physician and pharmacist – in some of the acute trusts in the region and will be seeking to expand this further in work in collaboration with the West Midlands Academic Health Sciences Network.

The number of reports from the region rose, as did the percentage of serious reports

3. YELLOW CARD DATA

Number of reports


Year	Number of reports	as percentage of national reports
2013/14	1114	6.4%
2012/13	889	6.2%
2011/12	974	7.4%
2010/11	879	7.2%
2009/10	915	7.7%

Serious reports

Year	Number of serious reports	as percentage of total reports
2013/14	596	54%
2012/13	485	55%
2011/12	544	56%
2010/11	481	55%
2009/10	494	54%

Fatal reports

Year	Number of fatal reports	as percentage of total reports
2013/14	19	1.7%
2012/13	16	1.8%
2011/12	29	3%
2010/11	34	3.9%
2009/10	18	2%



Age banding

Age range	percentage of reports 2013/14	percentage of reports 2012/13	percentage of reports 2011/12	percentage of reports 2010/11	percentage of reports 2009/10
<18	12%	8%	9%	13%	17%
18-24	4%	6%	6%	6%	7%
25-34	8%	9%	9%	9%	9%
35-44	11%	11%	10%	13%	12%
45-54	14%	12%	16%	11%	12%
55-64	14%	14%	13%	14%	14%
65-74	16%	20%	17%	13%	13%
75-84	13%	11%	10%	13%	7%
>85	2%	5%	3%	3%	2%
unknown	4%	5%	6%	6%	6%
Total	1114	889	974	879	915

Source of report

Reporter qualification	2013/14	2012/13	2011/12	2010/11	2009/10
Carer	9	6	7	5	6
Community Pharmacist	90	61	44	24	34
Consumer or other non-health professional					2
Coroner	1	1			
Dentist	8	1	3	3	3
GP	248	236	229	190	192
Healthcare Assistant	3		2		
Hospital Doctor	155	144	191	184	143
Hospital Health Professional	31	48	63	51	63
Hospital Nurse	85	60	68	66	67
Hospital Pharmacist	92	98	68	36	57
Nurse	131	91	102	105	140
Optometrist				1	
Other Health Professional	39	26	45	63	36
Parent	24	11	10	8	15
Patient	135	77	84	90	97
Pharmacist	16	8	28	12	29
Physician	11	8	12	39	31
Radiographer	11	10	21		

We have created a number of additional graphs to examine some local trends in reporting.

Figure 1: All Patient Reports (combined patient, carer, and parent reports)




Figure 2: All hospital Reports (Combination of hospital doctor, hospital nurse, hospital pharmacist & hospital other healthcare professional)




Figure 3: All Pharmacist Reports (Combination of pharmacist, community pharmacist, & hospital pharmacist).




Figure 4: Hospital Doctor Reports




Figure 5: All Healthcare Professional Reports




Figure 6: All Nurse Reports (Nurse, and Hospital Nurse)





Figure 7: General Practitioner Reports



Top 10 drugs

The top 12 drugs listed as suspect drug are shown below

Drug	Total
influenza vaccine ▼	51
varenicline	26
rivaroxaban	26
varicella-zoster vaccine	25
rotavirus vaccine ▼	20
denosumab ▼	17
ramipril	17
citalopram	16
adalimumab	15
human papilloma virus vaccine	14
amlodipine	14
pneumococcal vaccine	14

4. PROMOTIONAL ACTIVITIES

We have promoted the scheme with various talks and lectures during the year. Details of them are listed below.

Teaching

Meeting	Time	Number of participants	Number of sessions
Regional Medicines Information pharmacists	1 hour	20	2
University of Birmingham roadshow to 5 th year medical students	whole day	120	3
MHRA SpR training day (attended)	whole day	40	1
Birmingham University MSc lectures in toxicology	4 hours	20	1
Birmingham University medical school – safe prescribing lecture	6 hours	460	1
Drug Safety Induction talks	1 hour	10–30	26
Warfarin interactions and Yellow Card scheme: Birmingham University Primary care unit	1 hour	15–25	6
Drug Interactions and Pharmacovigilance module – MSc Experimental Therapeutics	1 hour	10	1
Monitoring ADRs and the Yellow Card system: risk management of ADRs – MSc Experimental Therapeutics	1 hour	10	1
Is any ADR non-dose-related? – MSc Experimental Therapeutics	1 hour	10	1
Birmingham University medical school – Nuts and bolts	2 hours	460	1
Medication Errors and Adverse Drug Reactions – Promoting effective reporting of events – WMAHSN event	30 minutes	80	1
Improving Patient Safety	30 minutes	40	1
Walsall manor Hospital Grand Round	1 hour	30	1

BCH pharmacists' meeting	1 hour	10	2
--------------------------	--------	----	---

Poster presented

The effect of an elearning module on junior doctors' knowledge of adverse drug reactions. Presented at the 13th Annual Meeting of ISOP in Pisa. October 2013.

Lectures given

Pharmacology, Pharmacy and Therapeutics Seminar, University of Birmingham. "Getting curves straight..."

Postgraduate Trainees, Russells Hall Hospital. "Medication errors."

British Association of Forensic Scientists, Guy's Hospital London. "Medicinal Aspects of Murder."

Regional Medical Information Pharmacists, Burton-on-Trent. "The Yellow Card Scheme."

Academic Health Sciences Network, Solihull. "Medication Errors and Adverse Drug Reactions – Promoting effective reporting of adverse events."

Birmingham Graduates Society, Birmingham. "Medical aspects of murder."

Burton District Hospital, Burton-on-Trent. "Adverse Drug Reactions."

South Asian Chapter of the American College of Clinical Pharmacologists, Mumbai. "How Drug & Therapeutics Committees make decisions."

European Association of Poisons Centres and Clinical Toxicologists, Brussels. "The future toxicology of food and drink."

Dowling Club Travelling Lectures, Medical University of Kazan, Tartarstan (Russian Federation). "Adverse drug reactions and the skin."

SIR Institute for Pharmacy Practice and Policy, de KNMP en de afdeling klinische farmacie en het Scientific Institute of Quality in Healthcare van het Radboud UMC, Nijmegen. "A perspective on patient safety.'

6. PUBLICATIONS AND CONFERENCES

Publications for 2013/14 include:

- Anton C. Adverse drug reactions and social media. *Adverse Drug Reaction Bulletin* 286.1 (2014): 1103-1106.
- Anton C. Encouraging the reporting of adverse drug reactions. *Adverse Drug Reaction Bulletin* 282.1 (2013): 1087-1090.
- Coleman J.J., Ferner R.E. Fundamentals of lung auscultation. *The New England journal of medicine*. 370 (21) (pp 2052), 2014.
- Coleman JJ, Hodson J, Brooks HL, Rosser D. Missed medication doses in hospitalised patients: a descriptive account of quality improvement measures and time series analysis. *International journal for quality in health care* 2013; 25 (5): 564-572
- Cox AR, Anton C, Thomas SK, Coleman JJ, Ferner RE. The effect of an elearning module on junior doctors' knowledge of adverse drug reactions. *Drug Safety* 2013; 36(9): 885-6.
- Cox AR. "Regulation of herbal drugs: a pragmatic public health approach?." *BMJ* 348 (2014).
- Cox AR. Cardiovascular risk and NSAIDs: prescribing slow to change. *Prescriber* 2013; 24(8): 5-6.
- Cresswell K, Coleman J, Slee A, Morrison Z, Sheikh A. A toolkit to support the implementation of electronic prescribing systems into UK hospitals: preliminary recommendations. *Journal of the Royal Society of Medicine* 2014; 107 (1): 8-13.

- Ferner R. A bee in the bonnet about honey and healing. *BMJ (Online)*. 347 (7922) , 2013. Article Number: f5015.
- Ferner R. A fat chance of slimming. *BMJ (Clinical research ed.)*. 347 , 2013. Article Number: f7389.
- Ferner R. Drug tales and other stories: Hallucination. *BMJ (Online)*. 347 (7917) , 2013. Article Number: f4570.
- Ferner R. Hallucination. *BMJ (Clinical research ed.)*. 347 , 2013. Article Number: f4570.
- Ferner R. Piquancy. *BMJ (Online)*. 346 (7909) , 2013. Article Number: f2938.
- Ferner R.E. Harms from medicines: Inevitable, in error or intentional. *British Journal of Clinical Pharmacology*. 77 (3) (pp 403-409), 2014.
- Ferner R.E., Mackenzie A.A., Aronson J.K. The adverse effects of nitrous oxide. *Adverse Drug Reaction Bulletin*. (285) (pp 1099-1102), 2014.
- Floor-Schreudering A., Geerts A.F.J., Aronson J.K., Bouvy M.L., Ferner R.E., De Smet P.A.G.M. Checklist for standardized reporting of drug-drug interaction management guidelines. *European Journal of Clinical Pharmacology*. 70 (3) (pp 313-318), 2014.
- Langford N.J., Ferner R.E. The medico-legal significance of pharmacokinetic interactions with ethanol. *Medicine, Science and the Law*. 53 (1) (pp 1-5), 2013
- McDowell S.E., Thomas S.K., Coleman J.J., Aronson J.K., Ferner R.E. A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy. *Journal of the Royal Society of Medicine* 2013; 106.3: 87-95.
- McLroy G, Thomas SK, Coleman JJ. Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing. *Journal of Public Health* 2014; fdu023
- Moss C., Ferner R.E. The British medical journal and prescribing of minocycline for acne. *British Journal of Dermatology*. 168 (3) (pp 667-668), 2013.
- Thomas SK, McDowell SE, Coleman JJ et al. Developing consensus on hospital prescribing indicators of potential harms amenable to decision support. *British journal of clinical pharmacology* 2013; 76 (5): 797-809.

7. RESEARCH

Our current research activity is concerned with adverse drug reactions, including classification, monitoring, and the patient experience of adverse drug reactions and the Yellow Card scheme.